Cargando…

Immunization with an adenovirus-vectored TB vaccine containing Ag85A-Mtb32 effectively alleviates allergic asthma

ABSTRACT: Current treatments for allergic asthma primarily ameliorate symptoms rather than inhibit disease progression. Regulating the excessive T helper type 2 (Th2) responses may prevent asthma exacerbation. In this study, we investigated the protective effects of Ad5-gsgAM, an adenovirus vector c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yiling, Feng, Ying, Li, Liang, Ye, Xianmiao, Wang, Jinlin, Wang, Qian, Li, Pingchao, Li, Na, Zheng, Xuehua, Gao, Xiang, Li, Chufang, Li, Feng, Sun, Baoqing, Lai, Kefang, Su, Zhong, Zhong, Nanshan, Chen, Ling, Feng, Liqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859035/
https://www.ncbi.nlm.nih.gov/pubmed/29302700
http://dx.doi.org/10.1007/s00109-017-1614-5
_version_ 1783307736197365760
author Zhang, Yiling
Feng, Ying
Li, Liang
Ye, Xianmiao
Wang, Jinlin
Wang, Qian
Li, Pingchao
Li, Na
Zheng, Xuehua
Gao, Xiang
Li, Chufang
Li, Feng
Sun, Baoqing
Lai, Kefang
Su, Zhong
Zhong, Nanshan
Chen, Ling
Feng, Liqiang
author_facet Zhang, Yiling
Feng, Ying
Li, Liang
Ye, Xianmiao
Wang, Jinlin
Wang, Qian
Li, Pingchao
Li, Na
Zheng, Xuehua
Gao, Xiang
Li, Chufang
Li, Feng
Sun, Baoqing
Lai, Kefang
Su, Zhong
Zhong, Nanshan
Chen, Ling
Feng, Liqiang
author_sort Zhang, Yiling
collection PubMed
description ABSTRACT: Current treatments for allergic asthma primarily ameliorate symptoms rather than inhibit disease progression. Regulating the excessive T helper type 2 (Th2) responses may prevent asthma exacerbation. In this study, we investigated the protective effects of Ad5-gsgAM, an adenovirus vector carrying two mycobacterial antigens Ag85A and Mtb32, against allergic asthma. Using an ovalbumin (OVA)-induced asthmatic mouse model, we found that Ad5-gsgAM elicited much more Th1-biased CD4(+)T and CD8(+)T cells than bacillus Calmette-Guérin (BCG). After OVA challenge, Ad5-gsgAM-immunized mice showed significantly lowered airway inflammation in comparison with mice immunized with or without BCG. Total serum immunoglobulin E and pulmonary inducible-nitric-oxide-synthase were efficiently reduced. The cytokine profiles in bronchial-alveolar-lavage-fluids (BALFs) were also modulated, as evidenced by the increased level of interferon-γ (IFN-γ) and the decreased level of interleukin (IL)-4, IL-5, and IL-13. Anti-inflammatory cytokine IL-10 was sharply increased, whereas pro-inflammatory cytokine IL-33 was significantly decreased. Importantly, exogenous IL-33 abrogated the protective effects of Ad5-gsgAM, revealing that the suppression of IL-33/ST2 axis substantially contributed to protection against allergic inflammation. Moreover, regulatory T cells were essential for regulating aberrant Th2 responses as well as IL-33/ST2 axis. These results suggested that modulating the IL-33/ST2 axis via adenovirus-vectored mycobacterial antigen vaccination may provide clinical benefits in allergic inflammatory airways disease. KEY MESSAGES: •Ad5-gsgAM elicits Th1 responses and suppresses Th2-mediated allergic asthma in mice. •Ad5-gsgAM inhibits IL-33/ST2 axis by reducing IL-33 secretion but not ILC2 recruiting. •Treg is essential for modulating Th2 responses and IL-33/ST2 axis by Ad5-gsgAM. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00109-017-1614-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5859035
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-58590352018-03-22 Immunization with an adenovirus-vectored TB vaccine containing Ag85A-Mtb32 effectively alleviates allergic asthma Zhang, Yiling Feng, Ying Li, Liang Ye, Xianmiao Wang, Jinlin Wang, Qian Li, Pingchao Li, Na Zheng, Xuehua Gao, Xiang Li, Chufang Li, Feng Sun, Baoqing Lai, Kefang Su, Zhong Zhong, Nanshan Chen, Ling Feng, Liqiang J Mol Med (Berl) Original Article ABSTRACT: Current treatments for allergic asthma primarily ameliorate symptoms rather than inhibit disease progression. Regulating the excessive T helper type 2 (Th2) responses may prevent asthma exacerbation. In this study, we investigated the protective effects of Ad5-gsgAM, an adenovirus vector carrying two mycobacterial antigens Ag85A and Mtb32, against allergic asthma. Using an ovalbumin (OVA)-induced asthmatic mouse model, we found that Ad5-gsgAM elicited much more Th1-biased CD4(+)T and CD8(+)T cells than bacillus Calmette-Guérin (BCG). After OVA challenge, Ad5-gsgAM-immunized mice showed significantly lowered airway inflammation in comparison with mice immunized with or without BCG. Total serum immunoglobulin E and pulmonary inducible-nitric-oxide-synthase were efficiently reduced. The cytokine profiles in bronchial-alveolar-lavage-fluids (BALFs) were also modulated, as evidenced by the increased level of interferon-γ (IFN-γ) and the decreased level of interleukin (IL)-4, IL-5, and IL-13. Anti-inflammatory cytokine IL-10 was sharply increased, whereas pro-inflammatory cytokine IL-33 was significantly decreased. Importantly, exogenous IL-33 abrogated the protective effects of Ad5-gsgAM, revealing that the suppression of IL-33/ST2 axis substantially contributed to protection against allergic inflammation. Moreover, regulatory T cells were essential for regulating aberrant Th2 responses as well as IL-33/ST2 axis. These results suggested that modulating the IL-33/ST2 axis via adenovirus-vectored mycobacterial antigen vaccination may provide clinical benefits in allergic inflammatory airways disease. KEY MESSAGES: •Ad5-gsgAM elicits Th1 responses and suppresses Th2-mediated allergic asthma in mice. •Ad5-gsgAM inhibits IL-33/ST2 axis by reducing IL-33 secretion but not ILC2 recruiting. •Treg is essential for modulating Th2 responses and IL-33/ST2 axis by Ad5-gsgAM. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00109-017-1614-5) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2018-01-04 2018 /pmc/articles/PMC5859035/ /pubmed/29302700 http://dx.doi.org/10.1007/s00109-017-1614-5 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Zhang, Yiling
Feng, Ying
Li, Liang
Ye, Xianmiao
Wang, Jinlin
Wang, Qian
Li, Pingchao
Li, Na
Zheng, Xuehua
Gao, Xiang
Li, Chufang
Li, Feng
Sun, Baoqing
Lai, Kefang
Su, Zhong
Zhong, Nanshan
Chen, Ling
Feng, Liqiang
Immunization with an adenovirus-vectored TB vaccine containing Ag85A-Mtb32 effectively alleviates allergic asthma
title Immunization with an adenovirus-vectored TB vaccine containing Ag85A-Mtb32 effectively alleviates allergic asthma
title_full Immunization with an adenovirus-vectored TB vaccine containing Ag85A-Mtb32 effectively alleviates allergic asthma
title_fullStr Immunization with an adenovirus-vectored TB vaccine containing Ag85A-Mtb32 effectively alleviates allergic asthma
title_full_unstemmed Immunization with an adenovirus-vectored TB vaccine containing Ag85A-Mtb32 effectively alleviates allergic asthma
title_short Immunization with an adenovirus-vectored TB vaccine containing Ag85A-Mtb32 effectively alleviates allergic asthma
title_sort immunization with an adenovirus-vectored tb vaccine containing ag85a-mtb32 effectively alleviates allergic asthma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859035/
https://www.ncbi.nlm.nih.gov/pubmed/29302700
http://dx.doi.org/10.1007/s00109-017-1614-5
work_keys_str_mv AT zhangyiling immunizationwithanadenovirusvectoredtbvaccinecontainingag85amtb32effectivelyalleviatesallergicasthma
AT fengying immunizationwithanadenovirusvectoredtbvaccinecontainingag85amtb32effectivelyalleviatesallergicasthma
AT liliang immunizationwithanadenovirusvectoredtbvaccinecontainingag85amtb32effectivelyalleviatesallergicasthma
AT yexianmiao immunizationwithanadenovirusvectoredtbvaccinecontainingag85amtb32effectivelyalleviatesallergicasthma
AT wangjinlin immunizationwithanadenovirusvectoredtbvaccinecontainingag85amtb32effectivelyalleviatesallergicasthma
AT wangqian immunizationwithanadenovirusvectoredtbvaccinecontainingag85amtb32effectivelyalleviatesallergicasthma
AT lipingchao immunizationwithanadenovirusvectoredtbvaccinecontainingag85amtb32effectivelyalleviatesallergicasthma
AT lina immunizationwithanadenovirusvectoredtbvaccinecontainingag85amtb32effectivelyalleviatesallergicasthma
AT zhengxuehua immunizationwithanadenovirusvectoredtbvaccinecontainingag85amtb32effectivelyalleviatesallergicasthma
AT gaoxiang immunizationwithanadenovirusvectoredtbvaccinecontainingag85amtb32effectivelyalleviatesallergicasthma
AT lichufang immunizationwithanadenovirusvectoredtbvaccinecontainingag85amtb32effectivelyalleviatesallergicasthma
AT lifeng immunizationwithanadenovirusvectoredtbvaccinecontainingag85amtb32effectivelyalleviatesallergicasthma
AT sunbaoqing immunizationwithanadenovirusvectoredtbvaccinecontainingag85amtb32effectivelyalleviatesallergicasthma
AT laikefang immunizationwithanadenovirusvectoredtbvaccinecontainingag85amtb32effectivelyalleviatesallergicasthma
AT suzhong immunizationwithanadenovirusvectoredtbvaccinecontainingag85amtb32effectivelyalleviatesallergicasthma
AT zhongnanshan immunizationwithanadenovirusvectoredtbvaccinecontainingag85amtb32effectivelyalleviatesallergicasthma
AT chenling immunizationwithanadenovirusvectoredtbvaccinecontainingag85amtb32effectivelyalleviatesallergicasthma
AT fengliqiang immunizationwithanadenovirusvectoredtbvaccinecontainingag85amtb32effectivelyalleviatesallergicasthma